Kathleen N. Moore Discusses New PARP Inhibitors for Ovarian Cancer

Even after surgery and chemotherapy, I make sure to shine through cancer and any fear that stares at me.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

My genetic testing covered 648 gene variants. Of course, researchers only know the significance of a fraction of those variants.

CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.

The Food and Drug Administration green lit a first-in-human phase 1 clinical study of Innocell, a vaccine for the treatment of stage 3 and 4 ovarian cancer.

After my treatment ended for triple-negative breast cancer, I thought I was done with cancer — and then I was diagnosed with ovarian cancer.